Search





Search





Markets
/
Stocks
/
tenx
/

Tenax Therapeutics Inc

TENX

Add to Watchlist

14.520USD

+0.820+5.99%

Close 07-31 16:00（ET）Quotes delayed by 15 min

463.91MMarket Cap

LossP/E TTM

Tenax Therapeutics Inc

14.520

+0.820+5.99%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

+5.99%

5 Days

-0.07%

1 Month

-6.08%

6 Months

+12.12%

Year to Date

+19.11%

1 Year

+133.44%

Key Figures

15.040Open

15.520High

5.03KVolume

LossP/E TTM

LossP/E Dynamic

--Dividend TTM

0.02%Turnover Ratio

13.700Prev. Close

13.650Low

43.82KTurnover

LossP/E Static

4.08P/B

0.00%Div Yield TTM

-49.23%ROA

18.38052wk High

-0.01Volume Ratio

-17.60MNet Profit

31.95MShares

-1.4042EPS TTM

0.98Beta

-51.71%ROE

5.34052wk Low

13.65%Amplitude

--Gross Margin

463.91MMarket Cap

-3.60Reward/Risk

4.38%Risk Rate

TradingKey Stock Score of Tenax Therapeutics Inc

Currency: USD Updated: 2026-07-31

Key Insights

Tenax Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 64 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 35.22.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Tenax Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

64 / 385

Overall Ranking

139 / 4281

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Tenax Therapeutics Inc Highlights

StrengthsRisks

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -9.76, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 11.71M shares, increasing 31.18% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 718.86K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 4.55.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

35.222

Target Price

+157.10%

Upside Space

Tenax Therapeutics Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 10 analysts

Buy

Current Rating

35.222

Target Price

+157.10%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

496

Total

Median

Average

Company name

Ratings

Analysts

Tenax Therapeutics Inc

TENX

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Kymera Therapeutics Inc

KYMR

Insmed Inc

INSM

...

Indicators

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.593

Neutral

RSI(14)

43.387

Neutral

STOCH(KDJ)(9,3,3)

24.167

Sell

ATR(14)

1.207

High Vlolatility

CCI(14)

-150.452

Sell

Williams %R

98.246

Oversold

TRIX(12,20)

0.369

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

15.122

Sell

MA10

15.097

Sell

MA20

15.801

Sell

MA50

13.563

Buy

MA100

13.693

Buy

MA200

12.252

Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Tenax Therapeutics Inc Info

Ticker SymbolTENX

CompanyTenax Therapeutics Inc

CEOGiordano (Christopher T)

Websitehttp://www.tenaxthera.com/

Shareholders

Shareholders

Proportion

T. Rowe Price Associates, Inc.

10.71%

Ikarian Capital LLC

3.84%

Logos Global Management LP

2.32%

Morgan Stanley & Co. LLC

2.23%

Perceptive Advisors LLC

1.66%

Other

79.25%

Popular Instruments

FAQs

What is the current price of Tenax Therapeutics Inc (TENX)?



The current price of Tenax Therapeutics Inc (TENX) is 13.70.

What is the symbol of Tenax Therapeutics Inc?



The ticker symbol of Tenax Therapeutics Inc is TENX.

What is the 52-week high of Tenax Therapeutics Inc?



The 52-week high of Tenax Therapeutics Inc is 18.38.

What is the 52-week low of Tenax Therapeutics Inc?



The 52-week low of Tenax Therapeutics Inc is 5.34.

What is the market capitalization of Tenax Therapeutics Inc?



The market capitalization of Tenax Therapeutics Inc is 512.71M.

Is Tenax Therapeutics Inc (TENX) currently rated as Buy, Hold, or Sell?



According to analysts, Tenax Therapeutics Inc (TENX) has an overall rating of Buy, with a price target of 35.22.

What is the Earnings Per Share (EPS TTM) of Tenax Therapeutics Inc (TENX)?



The Earnings Per Share (EPS TTM) of Tenax Therapeutics Inc (TENX) is -1.34.